Volume 8, Number 10—October 2002
Correction, Vol. 8, No. 7
|Vancomycin use prescribing practice change||No. of ICUs (%) (n=50)||Vancomycin use before and after practice change|
|Change absent||Change present|
|Drug use evaluation||19 (38)||74.2||80.5||105.3||94.1||0.62|
|Redistributed HICPAC guidelines on VRE||9 (18)||79.4||84.6||116.0||90.6||0.34|
|Prior approval of vancomycin required||3 (6)||87.2||84.7||67.2||99.4||0.25|
|ICU-specific education on appropriate vancomycin use||9 (18)||75.9||83.3||132.1||96.3||0.01|
|Removed vancomycin from surgical prophylaxis||3 (6)||82.0||85.9||149.1||82.2||0.01|
aDefined daily doses per 1,000 patient-days.
bICARE, Intensive Care Antimicrobial Resistance Epidemiology; ICU, intensive-care units; HICPAC, Healthcare Infection Control Practices Advisory Committee; VRE, vancomycin-resistant enterococci.
dComponents of each major category are not mutually exclusive, so one ICU may be represented in several components of each category.
Medline reports the volume should be "8" not "7" in reference "Fridkin, Lawton, Edwards, Tenover, McGowan, Gaynes, et al., 2002".
- Page created: April 19, 2012
- Page last updated: April 19, 2012
- Page last reviewed: April 19, 2012
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)